TScan CEO David Southwell steps down; Gavin MacBeath named acting CEO

TScan Therapeutics, Inc.

David Southwell resigned as CEO, President, and Board member effective March 27, 2023; no disagreement with company.
Gavin MacBeath, Ph.D., appointed acting CEO effective March 28, 2023; will continue as Chief Scientific and Operating Officer.
Southwell receives 18 months salary continuation and COBRA; severance conditioned on release and compliance with restrictive covenants.
Company reaffirms cash runway into Q2 2024 with $120M cash as of Dec 31, 2022; clinical programs on track.
First patient dosed with TSC-101 on March 9, 2023; plans to provide preliminary safety/biomarker data by mid-year 2023.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Southwell

Chief Executive Officer and President

TCRX · TScan Therapeutics, Inc.

Effective: 2023-03-27
Successor: Gavin MacBeath
Filed: March 31, 2023, 7:59 PM ET

On March 27, 2023, Mr. David Southwell stepped down from his roles as Chief Executive Officer and President of TScan Therapeutics, Inc. (the “Company”), and as a member of the Board of Directors of the Company (the “Board”), effective immediately.

Appointed (interim)

Gavin MacBeath

acting Chief Executive Officer

TCRX · TScan Therapeutics, Inc.

Effective: 2023-03-28
Filed: March 31, 2023, 7:59 PM ET

On March 28, 2023, the Board appointed Gavin MacBeath, Ph.D., as acting Chief Executive Officer of the Company, effective as of March 28, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Southwell resigned as Chief Executive Officer and President at TScan Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer and President

Exact text from the filing

On March 27, 2023, Mr. David Southwell stepped down from his roles as Chief Executive Officer and President of TScan Therapeutics, Inc. (the “Company”), and as a member of the Board of Directors of the Company (the “Board”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gavin MacBeath was appointed as acting Chief Executive Officer at TScan Therapeutics, Inc..

Action: appointed
Role: acting Chief Executive Officer

Exact text from the filing

On March 28, 2023, the Board appointed Gavin MacBeath, Ph.D., as acting Chief Executive Officer of the Company, effective as of March 28, 2023.

View on SEC.gov

TScan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-086922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.